Insider Selling: Amicus Therapeutics, Inc. (FOLD) Insider Sells 29,914 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Hung Do sold 29,914 shares of Amicus Therapeutics stock in a transaction on Friday, May 19th. The shares were sold at an average price of $8.00, for a total value of $239,312.00. Following the sale, the insider now directly owns 474,438 shares of the company’s stock, valued at $3,795,504. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up 7.28% during midday trading on Friday, hitting $9.43. The stock had a trading volume of 4,713,439 shares. The stock has a 50-day moving average price of $7.93 and a 200 day moving average price of $6.70. The firm’s market cap is $1.35 billion. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $9.61.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.02. The business had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $4.16 million. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post ($1.45) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

ILLEGAL ACTIVITY WARNING: “Insider Selling: Amicus Therapeutics, Inc. (FOLD) Insider Sells 29,914 Shares of Stock” was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/06/16/hung-do-sells-29914-shares-of-amicus-therapeutics-inc-fold-stock-updated-updated.html.

Institutional investors have recently modified their holdings of the company. State Street Corp raised its position in shares of Amicus Therapeutics by 12.2% in the fourth quarter. State Street Corp now owns 5,715,947 shares of the biopharmaceutical company’s stock worth $28,386,000 after buying an additional 622,349 shares in the last quarter. Creative Planning raised its stake in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,900 shares during the period. Norges Bank acquired a new stake in shares of Amicus Therapeutics during the fourth quarter worth $5,064,000. Berson & Corrado Investment Advisors LLC increased its stake in shares of Amicus Therapeutics by 16.8% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 47,525 shares of the biopharmaceutical company’s stock worth $339,000 after buying an additional 6,825 shares in the last quarter. Finally, Guggenheim Capital LLC acquired a new stake in shares of Amicus Therapeutics during the fourth quarter worth $1,522,000.

Several research analysts recently weighed in on FOLD shares. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. J P Morgan Chase & Co set a $13.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 5th. Chardan Capital restated a “buy” rating and set a $12.50 target price on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Bank of America Corporation dropped their price target on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Finally, Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 21st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $11.46.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply